Business Description
Adagene Inc
ISIN : US0053291078
Share Class Description:
FRA:978: ADRTotal Employee Number:
128Description
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 11.9 | |||||
Equity-to-Asset | 0.45 | |||||
Debt-to-Equity | 0.18 | |||||
Debt-to-EBITDA | -0.36 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -1.59 | |||||
Beneish M-Score | 61.93 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -8.8 | |||||
3-Year EBITDA Growth Rate | 41.5 | |||||
3-Year EPS without NRI Growth Rate | 42.8 | |||||
3-Year FCF Growth Rate | 33.7 | |||||
3-Year Book Growth Rate | -27 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -31.88 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 88.81 | |||||
9-Day RSI | 80.14 | |||||
14-Day RSI | 73.41 | |||||
3-1 Month Momentum % | -9.04 | |||||
6-1 Month Momentum % | 101.33 | |||||
12-1 Month Momentum % | 101.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.07 | |||||
Quick Ratio | 3.07 | |||||
Cash Ratio | 2.96 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.1 | |||||
Shareholder Yield % | 4.43 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -279.47 | |||||
Net Margin % | -229.55 | |||||
EBITDA Margin % | -227.4 | |||||
FCF Margin % | -204.34 | |||||
OCF Margin % | -204.11 | |||||
ROE % | -42.68 | |||||
ROA % | -22.57 | |||||
ROIC % | -170.58 | |||||
3-Year ROIIC % | -280.27 | |||||
ROC (Joel Greenblatt) % | -1544.63 | |||||
ROCE % | -36.81 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 27.59 | |||||
PB Ratio | 5.99 | |||||
Price-to-Tangible-Book | 6 | |||||
EV-to-EBIT | -13.02 | |||||
EV-to-EBITDA | -13.02 | |||||
EV-to-Revenue | 29.6 | |||||
EV-to-FCF | -14.49 | |||||
Price-to-GF-Value | 0.32 | |||||
| Price-to-Net-Current-Asset-Value | 6.09 | |||||
| Price-to-Net-Cash | 6.7 | |||||
Earnings Yield (Greenblatt) % | -7.68 | |||||
FCF Yield % | -5.31 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Adagene Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 6.551 | ||
| EPS (TTM) (€) | -0.324 | ||
| Beta | -1.5579 | ||
| 3-Year Sharpe Ratio | 0.72 | ||
| 3-Year Sortino Ratio | 1.69 | ||
| Volatility % | 65.38 | ||
| 14-Day RSI | 73.41 | ||
| 14-Day ATR (€) | 0.150459 | ||
| 20-Day SMA (€) | 3.196 | ||
| 12-1 Month Momentum % | 101.33 | ||
| 52-Week Range (€) | 1.18 - 4.04 | ||
| Shares Outstanding (Mil) | 66.07 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Adagene Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Adagene Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-08-12 | In 40 days | ||
| General meeting for 2025 | 2026-07-07 | In 4 days | ||
| Guidance call for 2026 | 2026-05-19 14:30 | 2.90 (+0.69%) | ||
| Annual report for 2025 | 2026-04-01 | 3.16 (-1.86%) | ||
| Fourth quarter earnings results for 2025 | 2026-04-01 | 3.16 (-1.86%) | ||
| Leerink Global Healthcare Conference | 2026-03-09 16:20 | 2.48 (-0.80%) | ||
| Oppenheimer 36th Annual Healthcare Life Sciences Conference (Virtual) | 2026-02-25 16:00 | 1.64 (+0.00%) | ||
| Guidance call for 2026 | 2026-02-11 16:30 | 1.64 (+0.00%) | ||
| Morgan Stanley 23rd Annual Global Healthcare Conference | 2025-09-10 07:00 | 2.02 (+2.02%) | ||
| H.C. Wainwright 27th Annual Global Investment Conference | 2025-09-08 11:00 | 1.76 (-1.12%) |
Show
Entries
Adagene Inc Frequently Asked Questions
What is Adagene Inc(FRA:978)'s stock price today?
The current price of FRA:978 is €4.02. The 52 week high of FRA:978 is €4.04 and 52 week low is €1.18.
When is next earnings date of Adagene Inc(FRA:978)?
The next earnings date of Adagene Inc(FRA:978) is 2026-08-12 Est..
Does Adagene Inc(FRA:978) pay dividends? If so, how much?
Adagene Inc(FRA:978) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Adagene Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers